Mary Caffrey
Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
Articles
Fine-Tuning AI Tools to Make Meaningful Predictions in Cancer
Anant Madabhushi, PhD, of Emory University, told attendees at the International Myeloma Society 21st Annual Meeting & Exposition how artificial intelligence's (AI) full potential in cancer care depends on its algorithms being validated by completed clinical trials.
Reaching Consensus on Defining, Treating High-Risk Myeloma
A new consensus definition for high-risk myeloma patients and promising results from trials dedicated to their care may offer a "paradigm shift" in treatment, experts say at the International Myeloma Society 21st Annual Meeting & Exposition.
After ODAC, What’s Next for MRD Testing in Multiple Myeloma?
April's vote of the FDA Oncology Drug Advisory Committee to support use of MRD-negative CR as an end point for accelerated approval represents a triumph of science, persistence, and collaboration, said panelists at the International Myeloma Society 21st Annual Meeting & Exposition.
Smoldering Multiple Myeloma: Risk Factors, Who to Treat, How to Treat
Speakers on precursor disease addressed distinctions between MGUS and smoldering multiple myeloma, risk stratification, and new thinking on the role of immunological aging, especially how it affects Black patients.
Korean Study Finds DOAC Use “Seems Effective” in Patients With MPNs
A study based on a decade's worth of Korean insurance data found that use of direct oral anticoagulants (DOACs) to address atrial fibrillation and venous thromboembolism in patients with myeloproliferative neoplasms (MPNs) is effective, with acceptable bleeding risk.
Review Explores Cardiovascular Risk in Certain Patients With MPNs
Inflammation and genetic mutations can drive cardiovascular complications in patients with myeloproliferative neoplasms, which include disorders such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
AJMC® Boston: Hot Topics, Leading Experts in Cancer Care Decision-Making
Attendees of the first Institute for Value-Based Medicine® regional event will hear top experts from Boston-area institutions speak about treating non–small cell lung cancer, targeting HER2 in breast cancer, and identifying biomarkers in sarcomas.
Top 5 Causes of Death on the First Labor Day Fueled by Harsh Working Life
Infectious diseases were the leading causes of death on the first Labor Day, just ahead of a major epidemiological shift that brought both vaccines to fight these deadly ailments but also the rise of cigarette smoking.
The Challenge With CAR T? It’s Not the Drug, It’s the Delivery
In this review, authors explain the supply chain issues of getting a life-saving treatment "vein to vein."
